Skip to main content

Address And Details

One Franklin Pkwy , San Mateo, CA 94403
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

The Fund seeks Capital appreciation. Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Funds investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the companys most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. In addition to its investments in biotechnology companies, the Fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. The Fund is a "non-diversified" fund, which means it generally invests a greater portion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund. The Fund may invest a substantial portion of its assets in equity securities of smaller capitalization companies, which are generally companies with market capitalizations of less than $1.5 billion at the time of the Funds investment. The Fund anticipates that, under normal conditions, it will invest more of its assets in U.S. securities than in securities of any other single country. It is currently anticipated that the Funds investments in foreign securities will not exceed 20% of its total assets. The Fund may buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts. The investment manager is a research driven, fundamental investor, pursuing a growth strategy. As a "bottom-up" investor focusing primarily on individual securities, the investment manager seeks companies that have identifiable drivers of future earnings growth and that present, in the investment manager's opinion, the best trade-off between that potential earnings growth, business and financial risk, and valuation. Also, in seeking sustainable growth characteristics, the investment manager looks for companies that it believes can produce sustainable earnings growth and cash flow growth or the potential to generate income.

Net Asset Value

as of 5:40 PM ET 01/18/2022

Performance

  • 1 Week
  • -5.66%
  • 1 Month
  • -9.79%
  • 3 Months
  • -26.07%
  • 1 Yr Return
  • -38.21%
  • 5 Yr Return
  • -19.35%

Equity Sector Breakdown

Health 77.68%
Technology 6.01%
Services 4.60%
Finance 1.81%
ConsumerDurables n/a
Energy n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Stocks 97.42%
ForeignStocks 5.88%
Preferred 0.51%
Cash 0.00%
Bonds 0.00%
Convertible 0.00%
Other 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 852.28 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -4.32 -6.30 -0.75
Beta 0.76 0.88 1.02
R Squared 0.34 0.39 0.33
Std Deviation 22.72 21.89 23.26
Sharpe Ratio 0.65 0.41 n/a

Purchase Information

as of 5:49 PM ET 01/14/2022
Minimum Initial $1000
Minimum Additional $0
Minimum Initial IRA $250

Performance

Timeframe Average Annual Current Performance Monthly As Of 12/31/2021 Average Annual Current Performance Quarterly As Of 12/31/2021 Avg Annual Current Performance Monthly As Of 12/31/2021 Avg Annual Current Performance Quarterly As Of 12/31/2021
1 Year
  • -17.70%
  • -17.70%
-17.70% -17.70%
3 Year
  • +12.96%
  • +12.96%
+12.96% +12.96%
10 Year
  • +13.93%
  • +13.93%
+13.93% +13.93%
Life Of Fund
  • +10.47%
  • +10.47%
+10.47% +10.47%

Top 10 Holdings

Symbol Company Name % Of Assets
REGN REGENERON PHARMACEUTICALS 5.60%
AMGN AMGEN INC 5.20%
HZNP HORIZON THERAPEUTICS PUBLIC 4.62%
ILMN ILLUMINA INC 4.45%
GILD GILEAD SCIENCES INC 4.39%
MRNA MODERNA INC 3.97%
MRTX MIRATI THERAPEUTICS INC 3.63%
BGEN BIOGEN INC 3.12%
VRTX VERTEX PHARMACEUTICALS INC 3.00%
ASND ASCENDIS PHARMA AS 2.97%

LATEST NEWS

Recent Articles from TheStreet

Google Lead

Google Might Soon Accept Crypto for Transactions

Tech and ad major Google wants to become the connective tissue for the entire consumer finance industry.

Donald Trump Lead

Trump Probe Finds 'Significant Evidence' of Fraud, New York AG Says

New York State Attorney General is seeking to question the former president and his two children.

Coca-Cola Lead

A Few Product Flops Later, Coca-Cola To Launch Mocha Version

Coca-Cola with Coffee Mocha reportedly "sips like a Coke and finishes like a coffee."

Contemporary Amperex Technology Co Ltd struck a two-year contract in February to supply batteries to Tesla, which produces its Model 3 electric cars at its Gigafactory in Shanghai. Photo: TNS

Electric Vehicle Checkpoint: Tesla Secures Plan-B For EV Batteries in Africa

See the latest news for the top stocks in the electric vehicle space including Ford, Lucid, Nio, Rivian and more.

Oil Prices Lead

Gasoline Prices at Multiyear High; Biden Scrambles to Lower Cost

Gasoline prices are the highest they've been in a decade as demand outpaces supply of crude.

SoFi Lead

Trading SoFi Stock as It Officially Becomes a Bank

SoFi Technologies has received regulatory approval to officially become a bank. Now here's how we're trading the stock.

18 shipping port sh

Supply Chain Woes: We're Not Out of the Woods Yet

A report from Everstream Analytics cites five ongoing risks, including ocean freight bottlenecks and increased regulation.

Housing Bubble

Will the U.S. Housing Market Crash in 2022?

Inflated prices and rising interest rates have people concerned that we could see a return of the 2008 housing crash.

Unilever Stock Rising on Possible Sir Kensington's Deal

Unilever Stock Surges After Brands Giant Says Won't Up $68 Billion GlaxoSmithKline Offer

Unilever said Wednesday that it won't increase its $68 billion offer for GlaxoSmithKline's healthcare division.

Exxon Mobil

Exxon Mobil Sets Goal for Net Zero Carbon Emissions by 2050

Energy major Exxon Mobil said it aimed to achieve net zero greenhouse gas emissions by 2050.